T2 Biosystems, Inc. (TTOO) |
|
0.2209 0.043 (23.89%)
|
09-29 16:00 |
|
Open: |
0.1991 |
Pre. Close: |
0.1783 |
|
High:
|
0.2398 |
Low:
|
0.1991 |
|
Volume:
|
107,628,004 |
Market Cap:
|
74(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:30:53 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.4 One year: 0.54 |
| Support: |
Support1: 0.14 Support2: 0.12 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.46 |
| Pivot: |
0.26  |
| Moving Average: |
MA(5): 0.2 MA(20): 0.28
MA(100): 0.21 MA(250): 0.91 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 11.7 %D(3): 7.4 |
| RSI: |
RSI(14): 44.3 |
| 52-week: |
High: 5.5 Low: 0.05 |
| Average Vol(K): |
3-Month: 121,093 (K) 10-Days: 116,161 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TTOO ] has closed above bottom band by 32.7%. Bollinger Bands are 28.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.24 - 0.24 |
0.24 - 0.24 |
|
Low:
|
0.2 - 0.2 |
0.2 - 0.2 |
|
Close:
|
0.22 - 0.22 |
0.22 - 0.22 |
|
Company Description |
|
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. |
Headline News |
Fri, 29 Sep 2023
Why SeaStar Medical Holding Shares Are Trading Higher By ... - Investing.com UK
Fri, 29 Sep 2023
The Cost to Borrow T2 (TTOO) Stock Is Up 130% in Just 10 Days - InvestorPlace
Fri, 29 Sep 2023
Unexplained Surge in T2 Biosystems Stock Price - Best Stocks
Fri, 29 Sep 2023
What's Going On With T2 Biosystems Stock Friday? - T2 Biosystems ... - Benzinga
Thu, 28 Sep 2023
T2 Biosystems 10% Owner Trades Company's Stock By Benzinga - Investing.com UK
Fri, 22 Sep 2023
Health Care Sector Update for 09/22/2023: TTOO, NLTX, NEPT - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
334 (M) |
| Shares Float |
283 (M) |
|
% Held by Insiders
|
0.7 (%) |
|
% Held by Institutions
|
19.4 (%) |
|
Shares Short
|
24,510 (K) |
|
Shares Short P.Month
|
15,590 (K) |
Stock Financials |
|
EPS
|
-2.37 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.16 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-393.2 |
|
Return on Assets (ttm)
|
-84.6 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-66.9 |
|
Gross Profit (p.s.)
|
-0.08 |
|
Sales Per Share
|
0.03 |
|
EBITDA (p.s.)
|
-0.16 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-52 (M) |
|
Levered Free Cash Flow
|
-23 (M) |
Stock Valuations |
|
PE Ratio
|
-0.1 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-1.48 |
|
Price to Sales
|
5.58 |
|
Price to Cash Flow
|
-1.43 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
